February 26, 2019
Gilead Sciences’ new hepatitis C drug Epclusa (sofosbuvir + velpatasvir) was launched in Japan on February 26 upon its NHI price listing the same day, making the first treatment option available for patients with decompensated cirrhosis. Epclusa encapsulates sofosbuvir, a...read more